Sistema cannabinoide y regulación de la conducta alimentaria
DOI:
https://doi.org/10.20882/adicciones.281Palabras clave:
sistema cannabinoide, obesidad, trastornos de la alimentación, ingesta, metabolismo energéticoResumen
Cada vez disponemos de más información que sugiere que el sistema cannabinoide es un mecanismo crucial en la regulación de la ingesta alimentaria y en el metabolismo energético. De ahí que próximamente se vaya a comercializar un antagonista cannabinoide, el rimonabant, para su uso en obesidad que, además de una pérdida de peso, consigue una mejora del denominado síndrome metabólico, con unos cambios en el metabolismo lipídico y glucídico no observados por otros fármacos antiobesidad actualmente comercializados. Se presenta una revisión de los conocimientos actuales sobre el tema y los datos de estudios propios: estudios genéticos de dicho sistema en los trastornos de la conducta alimentaria y en obesidad y estudios de localización de receptores cannabinoides en sitios relacionados con la ingesta. Dichos estudios apoyan un estado de hiperactividad cannabinoide en la obesidad y, además, dicha hiperactividad puede constituir un factor pronóstico.Citas
Abel, E.L. (1971). Effects of marihuana on the solution of anagrams, memory and appetite. Nature, 231, 260-261.
Abrams, D.I., Hilton, J.F., Leiser, R.J., Shade, S.B., Elbeik,
T.A. y Aweeka, F.T., et al. (2003). Short-term effects of cannabinoids in patients with HIV-1 infection: a randomized, placebo-controlled clinical trial. Annals of Internal Medicine, 139, 258-266.
Adami, M., Frati, P., Bertini, S., Kulkarni-Narla, A., Brown, D.R.
y de Caro, G., et al. (2002). Gastric antisecretory role and immunohistochemical localization of cannabinoid receptors in the rat stomach. British Journal of Pharmacology, 135, 1598-1606.
Ampuero, I. (2005). Análisis molecular de los genes del sistema
endocannabinoide CNR1 y FAAH en dos condiciones psiquiátricas: alcoholismo y depresión comórbida a la enfermedad de Parkinson. Tesis doctoral. Madrid: Universidad
Complutense.
Aranceta, J., Pérez, C., Serra, L., Ribas, L., Quiles, J. y Vioque,
J., Grupo colaboreativo para el Estudio de la Obesidad en España (2003). Prevalencia de obesidad en España: resultados del estudio SEEDO 2000. Medicina Clínica, 120, 608-612.
Arias, F., Sánchez, S., Gorgojo, J.J., Almódovar, F., Fernández, S. y Llorente, F. (2006). Diferencias clínicas entre pacientes obesos mórbidos con y sin atracones. Endocrinología y Nutrición, 53, 440-447.
Arias, F., Ampuero, I., Sagredo, O., Maestro, B., Almodovar,
F. y Sánchez, S., et al. (aceptado para publicación). Lack of association between polymorphisms in cannabinoid receptor genbe (CNR1) and fatty acid amide hydroxylase gene (FAAH) and eating disorders in a preliminary study. Psychiatric Genetics.
Arnone, M., Maruani, J., Chaperon, F., Thiebot, M.H., Poncelet, M. y Soubrie, P., et al. (1997). Selective inhibition of sucrose and ethanol intake by SR 141716, an antagonist of central cannabinoid (CB1) receptors. Psychopharmacology, 132, 104–106.
Avraham, Y., Ben-Shushan, D., Breuer, A., Zolotarev, O., Okon, A. y Fink, N., et al. (2004). Very low doses of delta 8-THC increase food consumption and alter neurotransmitter levels following weight loss. Pharmacology, Biochemistry and Behavior, 77, 675-684.
Avraham, Y., Menachem, A.B., Okun, A., Zlotarav, O., Abel,
N. y Mechoulam, R., et al. (2005). Effects of the endocannabinoid noladin ether on body weight, food consumption, locomotor activity, and cognitive index in mice. Brain Research Bulletin, 65, 117-123.
Bell, C.G., Walley, A.J. y Froguel, P. (2005). The genetics of
human obesity. Nature Review Genetics, 6, 221-234.
Bensaid, M., Gary-Bobo, M., Esclangon, A., Maffrand, J.P., Le
Fur, G. y Oury-Donat, F., et al. (2003). The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Molecular Pharmacology, 63, 908-914.
Berridge, K.C. (1996). Food reward: brain substrates of wanting and liking. Neuroscience and Biobehavioural Reviews, 20, 1-25.
Berthoud, H.R. (2002). Multiple neural systems controlling
food intake and body weight. Neuroscience and Biobehavioural Reviews, 26, 393-428.
Boyd, S.T. y Fremming, B.A. (2005). Rimonabant--a selective
CB1 antagonist. Annals of Pharmacotherapy, 39, 684-690.
Breivogel, C.S. y Childers, S.R. (1998). The functional neuroanatomy of brain cannabinoid receptors. Neurobiology of Diseases, 5, 417-431.
Broberger, C. (2005). Brain regulation of food intake and appetite: molecules and networks. Journal of Internal Medicine, 258, 301-327.
Budney, A.J., Hughes, J.R., Moore, B.A. y Vandrey, R. (2004). Review of the validity and significance of cannabis withdrawal syndrome. American Journal of Psychiatry, 161, 1967-1977.
Bulik, C.M., Sullivan, P.F. y Kendler, K.S. (2003). Genetic and environmental contributions to obesity and binge eating. International Journal of Eating Disorders, 33, 293-298.
Chiang, K.P., Gerber, A.L., Sipe, J.C. y Cravatt, B.F. (2004). Reduced cellular expression and activity of the P129T mutant of human fatty acid amide hydrolase: evidence for a link between defects in the endocannabinoid system and problem drug use. Human Molecular Genetics, 13, 2113-2119.
Colombo, G., Agabio, R., Diaz, G., Lobina, C., Reali, R. y Gessa, G.L. (1998). Appetite suppression and weight loss after the cannabinoid antagonist SR 141716. Life Sciences, 63, PL113-117.
Comings, D.E., Muhleman, D., Gade, R., Johnson, P., Verde,
R. y Saucier, G., et al. (1997). Cannabinoid receptor gene (CNR1): association with i.v. drug use. Molecular Psychiatry, 2, 161-168.
Cota, D., Marsicano, G., Tschop, M., Grubler, Y., Flachskamm,
C. y Schubert, M., et al. (2003). The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. Journal of Clinical Investigation, 112, 423-431.
Derbenev, A.V., Stuart, T.C. y Smith, B.N. (2004). Cannabinoids suppress synaptic input to neurones of the rat dorsal motor nucleus of the vagus nerve. Journal of Physiology, 559, 923-938.
Despres, J.P., Golay, A. y Sjostrom, L.; Rimonabant in Obesity-Lipids Study Group. (2005). Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. New England Journal of Medicine, 353, 2121-2134.
Di Marzo, V., Goparaju, S.K., Wang, L., Liu, J., Batkai, S. y Jarai, Z., et al. (2001). Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature, 410, 822-825.
Dong, C., Li, W.D., Geller, F., Lei, L., Li, D. y Gorlova, O.Y.,
et al. (2005). Possible genomic imprinting of three human obesity-related genetic loci. American Journal of Human Genetic, 76, 427-437.
Duarte, C., Alonso, R., Bichet, N., Cohen, C., Soubrie, P. y Thiebot, M.H. (2004). Blockade by the cannabinoid CB1 receptor antagonist, rimonabant (SR141716), of the potentiation by quinelorane of food-primed reinstatement of food-seeking behavior. Neuropsychopharmacology, 29, 911-920.
Engeli, S., Bohnke, J., Feldpausch, M., Gorzelniak, K., Janke, J. y Batkai, S., et al. (2005). Activation of the peripheral endocannabinoid system in human obesity. Diabetes, 54, 2838-2843.
Foltin, R.W., Brady, J.V. y Fischman, M.W. (1986). Behavioral
analysis of marijuana effects on food intake in humans. Pharmacology, Biochemistry and Behavior, 25, 577-582.
Foltin, R.W., Fischman, M.W. y Byrne, M.F. (1988). Effects of
smoked marijuana on food intake and body weight of humans living in a residential laboratory. Appetite, 11, 1-14.
Freedland, C.S., Poston, J.S. y Porrino, L.J. (2000). Effects of SR141716A, a central cannabinoid receptor antagonist, on food-maintained responding. Pharmacology, Biochemistry and Behavior, 67, 265-270.
Freedland, C.S., Sharpe, A.L., Samson, H.H. y Porrino, L.J. (2001). Effects of SR141716A on ethanol and sucrose self-administration. Alcoholism, Clinical and Experimental Research, 25, 277-282.
Gardner, E.L. (2005). Endocannabinoid signaling system and
brain reward: emphasis on dopamine. Pharmacology, Biochemistry and Behavior, 81, 263-284.
Gary-Bobo, M., Elachouri, G., Scatton, B., Le Fur, G., Oury-
Donat, F. y Bensaid, M. (2006). The cannabinoid CB1
receptor antagonist rimonabant (SR141716) inhibits cell proliferation and increases markers of adipocyte maturation in cultured mouse 3T3 F442A preadipocytes. Molecular Pharmacology, 69, 471-478.
Gomez, R., Navarro, M., Ferrer, B., Trigo, J.M., Bilbao, A. y
Del Arco, I., et al. (2002). A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding. Journal of Neuroscience, 22, 9612-9617.
Gorgojo, J.J., Arias, F., Almódovar, F., Sánchez, S., Ramos, J.A. y Alvarez, M., et al. (2006). Sistema cannabinoide y regulación de la conducta alimentaria: II. El polimorfismo corto (AAT)n del gen del receptor cannabinoide tipo 1 (CNR1) predice una menor pérdida de peso tras tratamiento médico o quirúrgico en
pacientes con obesidad mórbida. Póster presentado al XXXIII Congreso Socidrogalcohol. Cáceres.
Greenberg, I., Kuehnle, J., Mendelson, J.H. y Bernstein, J.G. (1976). Effects of marihuana use on body weight and caloric intake in humans. Psychopharmacology, 49, 79-84.
Grice, D.E., Halmi, K.A., Fichter, M.M., Strober, M., Woodside, D.B. y Treasure, J.T., et al. (2002). Evidence for a susceptibility gene for anorexia nervosa on chromosome 1. American Journal of Human Genetic, 70, 787-792.
Grinspoon, L. y Bakalar, J.B. (1993). Marihuana. The forbidden medicine. London: Yale University Press.
Gross, H., Ebert, M.H., Faden, V.B., Goldberg, S.C., Kaye, W.H. y Caine, E.D., et al. (1983). A double-blind trial of delta 9-tetrahydrocannabinol in primary anorexia nervosa. Journal of Clinical Psychopharmacology, 3, 165-171.
Hao, S., Avraham, Y., Mechoulam, R. y Berry, E.M. (2000). Low dose anandamide affects food intake, cognitive function, neurotransmitter and corticosterone levels in diet-restricted mice. European Journal of Pharmacology, 392, 147-156.
Haney, M., Ward, A.S., Comer, S.D., Foltin, R.W. y Fischman,
M.W. (1999a). Abstinence symptoms following smoked marijuana in humans. Psychopharmacology, 141, 395-404.
Haney, M., Ward, A.S., Comer, S.D., Foltin, R.W. y Fischman,
M.W. (1999b). Abstinence symptoms following oral THC administration to humans. Psychopharmacology, 141, 385-394.
Harrold, J.A. y Williams, G. (2006). Melanocortin-4 receptors,
beta-MSH and leptin: key elements in the satiety pathway. Peptides, 27, 365-371.
Hedley, A.A., Ogden, C.L., Johnson, C.L., Carroll, M.D., Curtin, L.R. y Flegal, K.M. (2004). Prevalence of overweight and obesity among US children, adolescents, and adults, 1999-2002. Journal of American Medical Association, 291, 2847-2850.
Higgs, S., Williams, C.M. y Kirkham, T.C. (2003). Cannabinoid
influences on palatability: microstructural analysis of sucrose drinking after delta(9)-tetrahydrocannabinol, anandamide, 2-arachidonoyl glycerol and SR141716. Psychopharmacology, 165, 370-377.
Hildebrandt, A.L., Kelly-Sullivan, D.M. y Black, S.C. (2003).
Antiobesity effects of chronic cannabinoid CB1 receptor antagonist treatment in diet-induced obese mice.
European Journal of Pharmacology, 462, 125-132.
Hollister, L.E. (1971). Hunger and appetite after single doses
of marihuana, alcohol, and dextroamphetamine. Clinical Pharmacology and Therapeutics, 12, 44-49.
Hollister, L. (2001). Marijuana (cannabis) as medicine. Journal of Cannabis Therapeutics, 1, 5-28.
Horvath, T.L. (2003). Endocannabinoids and the regulation
of body fat: the smoke is clearing. Journal of Clinical Investigation, 112, 323-326.
Jamshidi, N. y Taylor, D.A. (2001). Anandamide administration
into the ventromedial hypothalamus stimulates appetite in rats. British Journal of Pharmacology, 134, 1151-1154.
Jatoi, A., Windschitl, H.E., Loprinzi, C.L., Sloan, J.A., Dakhil,
S.R. y Mailliard, J.A., et al. (2002). Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study. Journal of Clinical Oncology, 20, 567-573.
Jbilo, O., Ravinet-Trillou, C., Arnone, M., Buisson, I., Bribes,
E. y Peleraux, A., et al. (2005). The CB1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance. FASEB Journal, 19, 1567-1569.
Jo, Y.H., Chen, Y.J., Chua, S.C. Jr, Talmage, D.A. y Role, L.W. (2005). Integration of endocannabinoid and leptin signaling in an appetite-related neural circuit. Neuron, 48, 1055-1066.
Kas, M.J., Van Elburg, A.A., Van Engeland, H. y Adan, R.A.
(2003). Refinement of behavioural traits in animals for the genetic dissection of eating disorders. European Journal of Pharmacology, 480, 13-20.
Kirkham, T.C., Williams, C.M., Fezza, F. y Di Marzo, V. (2002). Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol. British Journal of Pharmacology, 136, 550-557.
Kirkham, T.C. (2005). Endocannabinoids in the regulation of
appetite and body weight. Behavioral Pharmacology, 16, 297-313.
Koch, J.F. y Werner, N.A. (2000). Effects of the cannabinoid
antagonists AM 630 and AM 281 on deprivationinduced food intake in Lewis rats. Social Neuroscience Abstracts, 26, 569.
Koch , J. E . y Matthews, S.M. (2001 ) . Delt a9 tetrahydrocannabinol stimulates palatable food intake in Lewis rats: effects of peripheral and central administration. Nutritional Neuroscience, 4, 179-187.
Kola, B., Hubina, E., Tucci, S.A., Kirkham, T.C., Garcia, E.A. y
Mitchell, S.E., et al. (2005). Cannabinoids and ghrelin have both central and peripheral metabolic and cardiac effects via AMP-activated protein kinase. Journal of Biological Chemistry, 280, 25196-25201.
Lichtman, A.H. y Cravatt, B.F. (2005). Food for thought: endocannabinoid modulation of lipogenesis. Journal of Clinical Investigation, 115, 1130-1133.
Li, Z., Maglione, M., Tu, W., Mojica, W., Arterburn, D. y Shugarman, L.R., et al. (2005). Meta-analysis: pharmacologic treatment of obesity. Annals of Internal Medicine, 142, 532-546.
Liu, Y.L., Connoley, I.P., Wilson, C.A. y Stock, M.J. (2005).
Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lep ob /Lep ob mice. International Journal of Obesity, 29, 183-187.
Loos, R.J., Katzmarzyk, P.T., Rao, D.C., Rice, T., Leon, A.S.
y Skinner, J.S., et al., HERITAGE Family Study. (2003). Genome-wide linkage scan for the metabolic syndrome in the HERITAGE Family Study. Journal of Clinical Endocrinology and Metabolism, 88, 5935-5943.
Lupica, C.R., Riegel, A.C. y Hoffman, A.F. (2004). Marijuana
and cannabinoid regulation of brain reward circuits. British Journal of Pharmacology, 143, 227-234.
Martínez-Gonzalez, D., Bonilla-Jaime, H., Morales-Otal, A.,
Henriksen, S.J., Velázquez-Moctezuma, J. y Próspero-García, O. (2004). Oleamide and anandamide effects on food intake and sexual behavior of rats. Neuroscience Letters, 364, 1-6.
Mattes, R.D., Engelman, K., Shaw, L.M. y Elsohly, M.A. (1994). Cannabinoids and appetite stimulation. Pharmacology, Biochemistry and Behaviour, 49, 187-195.
McLaughlin, P.J., Winston, K., Swezey, L., Wisniecki, A., Aberman, J. y Tardif, D.J., et al. (2003). The cannabinoid CB1 antagonists SR 141716A and AM 251 suppress food intake and food-reinforced behavior in a variety of tasks in rats. Behavioral Pharmacology, 14, 583-588.
Miller, C.C., Murray, T.F., Freeman, K.G. y Edwards, G.L. (2004). Cannabinoid agonist, CP 55,940, facilitates intake of palatable foods when injected into the hindbrain. Physiology and Behavior, 80, 611-616.
Monteleone, P., Matias, I., Martiadis, V., De Petrocellis, L., Maj, M. y Di Marzo, V. (2005). Blood levels of the endocannabinoid anandamide are increased in anorexia nervosa and in binge-eating disorder, but not in bulimia nervosa. Neuropsychopharmacology, 30, 1216-1221.
Osei-Hyiaman, D., DePetrillo, M., Pacher, P., Liu, J., Radaeva,
S. y Batkai, S., et al. (2005). Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. Journal of Clinical Investigation, 115, 1298-1305.
Pagotto, U. y Pasquali, R. (2005). Fighting obesity and associated risk factors by antagonising cannabinoid type 1 receptors. Lancet, 365, 1363-1364.
Pagotto, U. y Pasquali, R. (2006). Endocannabinoids and energy metabolism. Journal of Endocrinological Investigation, 29(Suppl), 66-76.
Pazos, R., Tolón, R.M., Benito, C., Nuñez, E., Arias, F. y Gorgojo, J.J., et al. (2006). Sistema cannabinoide y regulación de la conducta alimentaria: III. El receptor para cannabinoides CB1 y la enzima hidrolasa de ácidos grasos (FAAH) están presentes en la mucosa gástrica humana. Póster presentado a XXXIII Congreso Socidrogalcohol. Cáceres.
Pi-Sunyer, F.X., Aronne, L.J., Heshmati, H.M., Devin, J. y Rosenstock, J., RIO-North America Study Group. (2006). Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. Journal of American Medical Association, 295, 761-775.
Ramos, J.A. y Fernández, J. (2000). Uso de los cannabinoides a través de la historia. Adicciones, 12 (supl. 2), 19-30.
Ravinet Trillou, C., Arnone, M., Delgorge, C., Gonalons, N.,
Keane, P. y Maffrand, J.P., et al. (2003). Anti-obesity effect of SR141716, a CB1 receptor antagonist, in dietinduced obese mice. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology, 284, R345-353.
Ravinet Trillou, C., Delgorge, C., Menet, C., Arnone, M. y
Soubrie, P. (2004). CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity. International Journal of Obesity and Related Metabolical Disorders, 28, 640-648.
Romero, J., Wenger, T., De Miguel, R., Ramos, J.A. yFernández-Ruiz, J.J. (1998). Cannabinoid receptor binding did not vary in several hypothalamic nuclei after hypothalamic deafferentation. Life Sciences, 63, 351-356.
Rowland, N.E., Mukherjee, M. y Robertson, K. (2001). Effects
of the cannabinoid receptor antagonist SR141716, alone and in combination with dexfenfluramine or naloxone, on food intake in rats. Psychopharmacology, 159, 111-116.
Scheen, A.J., Finer, N., Hollander, P., Jensen, M.D., Van Gaal, L.F.; RIO-Diabetes Study Group. (2006) Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet, 368, 1660-1672.
Schwabe, R.F. (2005). Endocannabinoids promote hepatic
lipogenesis and steatosis through CB1 receptors. Hepatology, 42, 959-961.
Siegfried, Z., Kanyas, K., Latzer, Y., Karni, O., Bloch, M. y Lerer, B., et al. (2004). Association study of cannabinoid receptor gene (CNR1) alleles and anorexia nervosa: differences between restricting and binging/purging subtypes. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics, 125, 126-130.
Simiand, J., Keane, M., Keane, P.E. y Soubrie, P. (1998). SR 141716, a CB1 cannabinoid receptor antagonist, selectively reduces sweet food intake in marmoset. Behavioral Pharmacology, 9, 179-181.
Sipe, J.C., Waalen, J., Gerber, A. y Beutler, E. (2005). Overweight and obesity associated with a missense polymorphism in fatty acid amide hydrolase (FAAH). International Journal of Obesity, 29, 755-759.
Stellar, E. (1954). The physiology of motivation. Psychological
Reviews, 61, 5-22.
Storr, M., Gaffal, E., Saur, D., Schusdziarra, V. y Allescher, H.D. (2002). Effect of cannabinoids on neural transmission in rat gastric fundus. Canadian Journal of Physiology and Pharmacology, 80, 67-76.
Tart, C.T. (1970). Marijuana intoxication common
experiences. Nature, 226, 701-704.
Thornton-Jones, Z.D., Vickers, S.P. y Clifton, P.G. (2005).
The cannabinoid CB1 receptor antagonist SR141716A
reduces appetitive and consummatory responses for food. Psychopharmacology, 179, 452-460.
Van Gaal, L.F., Rissanen, A.M., Scheen, A.J., Ziegler, O. y
Rossner, S., RIO-Europe Study Group. (2005). Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIOEurope study. Lancet, 365, 1389-1397.
Verty, A.N., McGregor, I.S. y Mallet, P.E. (2004). Consumption of high carbohydrate, high fat, and normal chow is equally suppressed by a cannabinoid receptor antagonist in non-deprived rats. Neuroscience Letters, 354, 217-220.
Vickers, S.P., Webster, L.J., Wyatt, A., Dourish, C.T. y Kennett,
G.A. (2003). Preferential effects of the cannabinoid CB1 receptor antagonist, SR 141716, on food intake and body weight gain of obese (fa/fa) compared to lean Zucker rats. Psychopharmacology, 167, 103-111.
Volicer, L., Stelly, M., Morris, J., McLaughlin, J. y Volicer, B.J. (1997). Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer’s disease. International Journal of Geriatric Psychiatry, 12, 913-919.
Wadman, M. (2006). Rimonabant adds appetizing choice to
slim obesity market. Nature Medicine, 12, 27.
Ward, S.J. y Dykstra, L.A. (2005). The role of CB1 receptors in sweet versus fat reinforcement: effect of CB1 receptor deletion, CB1 receptor antagonism (SR141716A) and CB1 receptor agonism (CP-55940). Behavioural Pharmacology, 16, 381-388.
Wiley, J.L., Burston, J.J., Leggett, D.C., Alekseeva, O.O., Razdan, R.K. y Mahadevan, A., et al. (2005). CB1 cannabinoid receptor-mediated modulation of food intake in mice. British Journal of Pharmacology, 145, 293-300.
Williams, C.M., Rogers, P.J. y Kirkham, T.C. (1998). Hyperphagia in pre-fed rats following oral delta9-THC. Physiology and Behavior, 65, 343-346.
Williams, C.M. y Kirkham, T.C. (1999). Anandamide induces
overeating: mediation by central cannabinoid (CB1) receptors. Psychopharmacology, 143, 315-317.
Williams, C.M. y Kirkham, T.C. (2002). Observational analysis
of feeding induced by Delta9-THC and anandamide. Physiology and Behavior, 76, 241-250.
Wynne, K., Stanley, S., McGowan, B. y Bloom, S. (2005).
Appetite control. Journal of Endocrinology, 184, 291-318.